Efficacy of Dalbavancin against Methicillin-Resistant Staphylococcus aureus in the Rat Granuloma Pouch Infection Model

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 4, 2004, Pages 1118-1123

  Jabés, Daniela ^a   Candiani, Gianpaolo ^a   Romanó, Gabriella ^a   Brunati, Cristina ^a   Riva, Simona ^a   Cavaleri, Marco ^a  

^a Vicuron Pharmaceuticals   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; LINEZOLID; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BODY WEIGHT; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXUDATE; GRANULOMA; HOSPITAL PATIENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS;

ACETAMIDES; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; FEMALE; GLYCOPEPTIDES; GRANULOMA; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICOPLANIN; VANCOMYCIN;

EID: 1642461461     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.4.1118-1123.2004     Document Type: Article

References (26)

1. Abramson, M. A., and D. J. Sexton. 1999. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect. Control Hosp. Epidemiol. 20:408-411.
2. Aucken, H. M., M. Ganner, S. Murchan, B. D. Cookson, and A. P. Johnson. 2002. A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J. Antimicrob. Chemother. 50:171-175.
3. Candiani, G., M. Abbondi, M. Borgonovi, G. Romano, and F. Parenti. 1999. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192.
4. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
5. Collignon, P. J. 2002. Antibiotic resistance. Med. J. Aust. 177:325-329.
6. Crowe, M., P. Ispahani, H. Humphreys, T. Kelley, and R. Winter. 1998. Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996. Eur. J. Clin. Microbiol. Infect. Dis. 17:377-384.
7. Dalhoff, A. 1986. The granuloma pouch, p. 123-137. In O. Zak and M. A. Sande (ed.), Experimental models in antimicrobial chemotherapy. Academic Press, London, United Kingdom.
8. Denis, O., C. Nonhoff, B. Byl, C. Knoop, S. Bobin-Dubreux, and M. J. Struelens. 2002. Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J. Antimicrob. Chemother. 50:383-391.
9. Dufour, P., Y. Gillet, M. Bes, G. Lina, F. Vandenesch, D. Floret, J. Etienne, and H. Richet. 2002. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin. Infect. Dis. 35:819-824.
10. Haddadin, A. S., S. A. Fappiano, and P. A. Lipsett. 2002. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad. Med. J. 78:385-392.
11. Hamilton-Miller, J. M. 2002. Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection 30:118-124.
12. Heym, B., M. Le Moal, L. Armand-Lefevre, and M. H. Nicolas-Chanoine. 2002. Multilocus sequence typing (MLST) shows that the 'Iberian' clone of methicillin-resistant Staphylococcus aureus has spread to France and acquired reduced susceptibility to teicoplanin. J. Antimicrob. Chemother. 50:323-329.
13. Hussain, F. M., S. Boyle-Vavra, P. B. Shete, and R. S. Daum. 2002. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis. 186:661-667.
14. Jones, R. N., D. J. Biedenbach, D. M. Johnson, and M. A. Pfaller. 2001. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. J. Chemother. 13:244-254.
15. Leighton, A., A. B. Gottlieb, M. B. Dorr, D. Jabes, G. Mosconi, C. Van-Saders, E. J. Mroszczak, K. C. M. Campbell, and E. Kelly. Tolerability, pharmacokinetics, and pharmacodynamics of intravenous dalbavancin in healthy volunteers. Antimicrob. Agents Chemother. 48:940-945.
16. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
17. Malabarba, A., and R. Ciabatti. 2001. Glycopeptide derivatives. Curr. Med. Chem. 8:1759-1773.
18. Mizobuchi, S., J. Minami, F. Jin, O. Matsushita, and A. Okabe. 1994. Comparison of the virulence of methicillin-resistant and methicillin-sensitive Staphylococcus aureus. Microbiol. Immunol. 38:599-605.
19. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standards, 4th ed. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
20. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved standards, 4th ed. M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Oramas-Shirey, M. P., L. V. Buchanan, C. L. Dileto-Fang, C. F. Dailey, C. W. Ford, D. H. Batts, and J. K. Gibson. 2001. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J. Antimicrob. Chemother. 47:349-352.
22. Seltzer, E., M. B. Dorr, B. P. Goldstein, M. Perry, J. A. Dowell, T. Henkel, et al. 2003. Once-weekly dalbavancin versus standard of care antimicrobial regimens for treatment of skin and soft tissue infections. Clin. Infect. Dis. 37:1298-1303.
23. Speller, D. C., A. P. Johnson, D. James, R. R. Marples, A. Charlett, and R. C. George. 1997. Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95. Lancet 350:323-325.
24. Steiert, M., and F. J. Schmitz. 2002. Dalbavancin (Biosearch Italia/Versicor). Curr. Opin. Investig. Drugs 3:229-233.
25. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, R. C. Moellering, and M. J. Ferraro. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358:207-208.
26. Voorn, G. P., J. Kuyvenhoven, W. H. Goessens, W. C. Schmal-Bauer, P. H. Broeders, J. Thompson, and M. F. Michel. 1994. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob. Agents Chemother. 38:487-493.